Important Announcements

Nondiscrimination Policy Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To read our full Nondiscrimination Statement, click here.

Welcome

This website is designed to help you understand cervical cancer screening and what the next steps are after an abnormal result. The Personalized Risk Assessment Tool will walk you through the steps that a doctor or healthcare provider may use when deciding management after an abnormal result.

To use this tool, you must have had a Pap test or HPV test in the past. You will need to look at your medical record (either using paper records or a patient portal) to use the tool because you need to enter exact medical terms.

Please choose the green button for the personalized risk assessment. If you do not have your medical record, or if you just want to learn more about screening and vaccination, click one of the additional information buttons.

 

ABOUT US: The content for this website was developed by researchers at Boston University, with input from the National Cancer Institute, Centers for Disease Control and Prevention, and American Cancer Society. Software was engineered by Aiden Taghinia. This website aims to help people without advanced understanding of medicine or medical terminology understand changes in screening and management guidelines. We developed this website because there are currently few resources available to help patients in this area. This website does not provide medical advice. For a complete evaluation, please see your healthcare provider. This website will be updated in response to guideline changes and in collaboration with the National Cancer Institute. Most recent update was: July 31, 2021.